Pfizer Inc. (NYSE:PFE) Position Reduced by First American Bank

First American Bank trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 22,046 shares of the biopharmaceutical company’s stock after selling 600 shares during the quarter. First American Bank’s holdings in Pfizer were worth $559,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in PFE. Tallon Kerry Patrick bought a new position in Pfizer during the 4th quarter valued at $509,000. Brighton Jones LLC lifted its position in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after buying an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC lifted its position in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after buying an additional 2,087 shares during the last quarter. Venturi Wealth Management LLC lifted its position in shares of Pfizer by 23.1% in the 4th quarter. Venturi Wealth Management LLC now owns 6,181 shares of the biopharmaceutical company’s stock worth $164,000 after buying an additional 1,159 shares during the last quarter. Finally, Ieq Capital LLC lifted its position in shares of Pfizer by 14.3% in the 4th quarter. Ieq Capital LLC now owns 320,472 shares of the biopharmaceutical company’s stock worth $8,502,000 after buying an additional 40,117 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on PFE. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Citigroup restated a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. The Goldman Sachs Group restated a “neutral” rating and issued a $25.00 price target (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Finally, Cantor Fitzgerald started coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price target on the stock. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $29.17.

Pfizer Trading Up 0.4%

Shares of NYSE:PFE opened at $23.97 on Friday. The company has a market cap of $136.27 billion, a PE ratio of 17.37, a P/E/G ratio of 0.87 and a beta of 0.57. The company’s 50-day moving average price is $23.26 and its 200 day moving average price is $24.90. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the previous year, the firm earned $0.82 EPS. Pfizer’s revenue was down 7.8% on a year-over-year basis. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, June 13th. Shareholders of record on Friday, May 9th were given a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.18%. Pfizer’s dividend payout ratio (DPR) is 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.